Your browser doesn't support javascript.
loading
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Yap, Timothy A; Daver, Naval; Mahendra, Mikhila; Zhang, Jixiang; Kamiya-Matsuoka, Carlos; Meric-Bernstam, Funda; Kantarjian, Hagop M; Ravandi, Farhad; Collins, Meghan E; Francesco, Maria Emilia Di; Dumbrava, Ecaterina E; Fu, Siqing; Gao, Sisi; Gay, Jason P; Gera, Sonal; Han, Jing; Hong, David S; Jabbour, Elias J; Ju, Zhenlin; Karp, Daniel D; Lodi, Alessia; Molina, Jennifer R; Baran, Natalia; Naing, Aung; Ohanian, Maro; Pant, Shubham; Pemmaraju, Naveen; Bose, Prithviraj; Piha-Paul, Sarina A; Rodon, Jordi; Salguero, Carolina; Sasaki, Koji; Singh, Anand K; Subbiah, Vivek; Tsimberidou, Apostolia M; Xu, Quanyun A; Yilmaz, Musa; Zhang, Qi; Li, Yuan; Bristow, Christopher A; Bhattacharjee, Meenakshi B; Tiziani, Stefano; Heffernan, Timothy P; Vellano, Christopher P; Jones, Philip; Heijnen, Cobi J; Kavelaars, Annemieke; Marszalek, Joseph R; Konopleva, Marina.
Affiliation
  • Yap TA; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TYap@mdanderson.org.
  • Daver N; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TYap@mdanderson.org.
  • Mahendra M; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kamiya-Matsuoka C; Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian HM; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ravandi F; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Collins ME; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Francesco MED; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.
  • Dumbrava EE; Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
  • Fu S; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao S; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gay JP; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gera S; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Han J; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hong DS; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour EJ; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ju Z; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Karp DD; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lodi A; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Molina JR; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baran N; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.
  • Ohanian M; Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
  • Pant S; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bose P; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Piha-Paul SA; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodon J; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Salguero C; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sasaki K; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Singh AK; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu QA; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yilmaz M; Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang Q; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Li Y; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bristow CA; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bhattacharjee MB; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tiziani S; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heffernan TP; Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Vellano CP; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jones P; Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Heijnen CJ; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.
  • Kavelaars A; Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
  • Marszalek JR; Department of Oncology, Dell Medical School, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA.
  • Konopleva M; Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Med ; 29(1): 115-126, 2023 01.
Article in En | MEDLINE | ID: mdl-36658425
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Document type: Article Affiliation country: Country of publication: